Cardlytics Securities Class Action Lawsuit
Analysis based on 6 articles · First reported Feb 02, 2025 · Last updated Mar 15, 2025
The market is negatively impacted by the alleged misleading statements and poor financial performance of Cardlytics, Inc., leading to significant stock price drops. The ongoing class action lawsuit initiated by Faruqi & Faruqi, LLP creates uncertainty for investors and could result in substantial financial penalties for Cardlytics, Inc.
Faruqi & Faruqi, LLP is investigating Cardlytics, Inc. for alleged violations of federal securities laws and has filed a class action lawsuit. The complaint alleges that Cardlytics, Inc. made false and misleading statements regarding its business operations, specifically concerning consumer engagement, incentives, billings, and revenue growth. These issues led to a significant increase in consumer incentives that the company could not offset with billings, resulting in slowed or declining revenue growth. On May 8, 2024, Cardlytics, Inc. reported an 8% year-over-year revenue increase in Q1 2024, despite a 12% increase in billings, due to a 20.2% rise in consumer incentives, causing its stock price to fall by 36.5%. On August 7, 2024, Cardlytics, Inc. announced a 9% year-over-year decrease in Q2 2024 revenue and a 3% decline in adjusted contribution, leading to a further 57.1% drop in its stock price. Additionally, Karim Temsamani stepped down as CEO and from the Board of Directors. James Wilson of Faruqi & Faruqi, LLP is encouraging investors who suffered losses to join the class action lawsuit, with a deadline of March 25, 2025, to seek the role of lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard